Immunotherapy before liver transplant for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of two immunotherapy drugs before a liver transplant can help people with advanced liver cancer (beyond standard size limits) receive a transplant successfully. The treatment aims to shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer that is outside the usual Milan criteria for transplant, but it has not spread to other organs.
- You are being evaluated for or are already on the liver transplant waiting list.
- You are able to receive a procedure called TACE or TARE, which delivers treatment directly to the liver tumor.
- Your liver function is reasonably good (Child-Pugh score B7 or better), and you are generally in good health (ECOG 0-1).
- You have not had prior systemic therapy (drugs that travel through the whole body) for your liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial tests combining radiation therapy with immunotherapy (AtezoBev) before a liver transplant for advanced liver cancer. The goal is to see if this approach can shrink tumors and make transplant possible for more people.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial tests whether giving an immunotherapy drug (atezolizumab) before liver surgery can help your immune system fight liver cancer more effectively. You would receive the drug before your planned surgery, and the study will compare your outcomes with those who have surgery alone.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.